Publications
Publications
Show Results For
- All HBS Web
(166)
- Faculty Publications (34)
Novartis
→
←
Page 2 of 34
Results
- July 2008 (Revised May 2017)
- Teaching Note
Financial Leadership in Novartis Consumer Health Businesses
By: Boris Groysberg and Geoff Marietta
Teaching Note for HBS No. 406-102. View Details
- March 2008
- Case
Novartis AG: Science-Based Business
By: H. Kent Bowen and Courtney Purrington
Novartis is a science-based drug company, which has important implications for its business strategy. It is one of the largest pharmaceutical companies in the world with over $38B in sales in 2007. Pharmaceuticals account for slightly over $24B of that total. In 2007,... View Details
- April 2006
- Case
Finance Leadership in Novartis Consumer Health Businesses
By: Boris Groysberg and Ingrid Vargas
Describes and contrasts the roles and challenges of three high-performing finance heads at Novartis Consumer Health businesses in Australia, Japan, and Venezuela. All three faced tremendous pressures in terms of managing time and limited resources, but the particular... View Details
- April 2003 (Revised October 2004)
- Case
Novartis: The Challenge of Success (B)
By: Sandra J. Sucher and Stacy McManus
When Dr. Daniel Vasella learned of the early Phase 1 trial results, he immediately decided what course of action Novartis would take. Students will be able to examine and assess the concrete steps, and the rationale behind them, that Novartis took in response to this... View Details
- January 2001 (Revised May 2003)
- Case
Novartis Pharma: The Business Unit Model
By: Srikant M. Datar, Carin-Isabel Knoop and Cate Reavis
In June 2000, Novartis reorganized its pharmaceutical business to form global business units in oncology, transplantation, ophthalmology, and mature products. The remaining primary care products continued to be managed within global functions (e.g., R&D and marketing).... View Details
- October 2000
- Supplement
Hans Fritz at Novartis Thailand (C)
By: Carin-Isabel Knoop and Michael Y. Yoshino
Supplements the (A) case. View Details
- October 2000
- Supplement
Hans Fritz at Novartis Thailand (D): The First 18 Months
By: Michael Y. Yoshino and Carin-Isabel Knoop
Supplements the (A) case. View Details
- May 2000
- Case
To Trim or Not to Trim: That Is the Question
By: Srikant M. Datar
Should Novartis drop 20% of its global pharmaceutical product brands that account for only 3% of its pharmaceutical revenues? View Details
- July 1999
- Supplement
Jan Eriksson of Novartis Indonesia
By: Christopher A. Bartlett and Carin-Isabel Knoop
A follow-up interview, in Summer 1998, with the protagonist of the Novartis Indonesia case series. He describes ongoing strategy and activities. View Details
- March 1999
- Case
Hans Fritz at Novartis Thailand (A): The First Month
By: Michael Y. Yoshino and Carin-Isabel Knoop
Dr. Hans Fritz is 37 years old when he arrives in Bangkok on March 1, 1998 to assume his position as general manager of Novartis Thailand. Novartis is the world's largest pharmaceutical company. He had lobbied to transition from a staff position to this line management... View Details
- March 1999 (Revised January 2001)
- Case
Hans Fritz at Novartis Thailand (B): The First Six Months
By: Michael Y. Yoshino and Carin-Isabel Knoop
Supplements the (A) case. View Details
- February 1998 (Revised November 1998)
- Case
Novartis (A): Being a Global Leader
By: Srikant M. Datar and Carin-Isabel Knoop
For the Novartis leaders, the decision to "use stretch budgets again next year" highlights the tension between candor and empowerment and command-and-control, between the new and the old, between high performance and business as usual, between Ciba and Sandoz.... View Details
- December 1996 (Revised June 2003)
- Case
Cynthia Hogan and the Birth of Novartis
An American woman heads an integration office for merger transition activities between two giant Swiss pharmaceutical companies. She needed to develop an implementation plan to shape the new global powerhouse. View Details